This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gu, A.-D.
Right arrow Articles by Zeng, Y.-X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, A.-D.
Right arrow Articles by Zeng, Y.-X.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, November 2008, p. 1684-1688, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00135-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evaluation of a Multianalyte Profiling Assay and an Enzyme-Linked Immunosorbent Assay for Serological Examination of Epstein-Barr Virus-Specific Antibody Responses in Diagnosis of Nasopharyngeal Carcinoma {triangledown} ,{dagger}

Ai-Di Gu,1,2 Hao-Yuan Mo,3 Yan-Bo Xie,1,2 Rou-Jun Peng,1,2 Jin-Xin Bei,1,2 Juan Peng,4 Miao-Yan Li,4 Li-Zhen Chen,1,2 Qi-Sheng Feng,1,2 Wei-Hua Jia,1,2 and Yi-Xin Zeng1,2*

State Key Laboratory of Oncology in South China,1 Departments of Experimental Research,2 Nasopharyngeal Carcinoma, Cancer Center,3 Da'an Gene Diagnostic Center, Sun Yat-Sen University, Guangzhou, China4

Received 3 April 2008/ Returned for modification 13 June 2008/ Accepted 26 August 2008

Assessment of antibody responses to Epstein-Barr virus (EBV) antigens has been used to assist in nasopharyngeal carcinoma (NPC) diagnosis by several methods. In this study, we evaluated an in-house Luminex multianalyte profiling (xMAP) technology and commercial enzyme-linked immunosorbent assay (ELISA) kits for serological examination of EBV-specific antibody responses in 135 NPC patients and 130 healthy controls. Four EBV biomarkers were measured: immunoglobulin A (IgA) against viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA1), diffused early antigen (EA-D), and IgG against EA-D. The sensitivities and specificities of the four markers ranged between 71.5 and 90% for xMAP assays and 80 and 92% for ELISA. Logistic regression analysis revealed that the combined markers in the xMAP assay had overall sensitivity and specificity values of 82% and 92%, respectively. The correlation coefficient (r) values for the xMAP assay and ELISA were lowest for IgA-VCA (0.468) and highest for IgA-EBNA1 (0.846); for IgA-EA-D and IgG-EA-D, the r values were 0.719 and 0.798, respectively. The concordances of the two methods for NPC discrimination were good (79 to 88%). Our results suggest that both the xMAP assay and ELISA are satisfactory for EBV antibody evaluation when multiple antigens are included.

* Corresponding author. Mailing address: Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, China. Phone: 86-20-8734-3333. Fax: 86-20-8734-3295. E-mail: zengyix{at}mail.sysu.edu.cn

{triangledown} Published ahead of print on 3 September 2008.

{dagger} Supplemental material for this article may be found at http://cvi.asm.org/.

Clinical and Vaccine Immunology, November 2008, p. 1684-1688, Vol. 15, No. 11
1071-412X/08/$08.00+0     doi:10.1128/CVI.00135-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»